← All trials
NCT02733185
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2016
- Primary completion
- Aug 1, 2021
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 1200
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Mt. Sinai Medical Center, MiamiLead sponsor
- Duke UniversityOverall official - principal investigator
- Mt. Sinai Medical Center, MiamiReponsible party - principal investigator
- National Center for Complementary and Integrative Health (NCCIH)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Duke UniversityCollaborator
- Icahn School of Medicine at Mount SinaiStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.